A rebound of COVID-19 symptoms in some patients after taking Pfizer’s antiviral Paxlovid may be related to a robust immune response rather than a weak one, U.S. government researchers reported on Thursday.
https://www.pharmalive.com/wp-content/uploads/2022/05/Evidence-mounts-for-need-to-study-Pfizers-Paxlovid-for-long-COVID-researchers-say-Reuters-5-5-22.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-10-07 02:43:012022-10-07 09:10:25COVID rebound after Pfizer treatment likely due to robust immune response, study finds
